Eli Lilly CEO says Medicare coverage of obesity drugs could 'change the game' for upcoming pill launch

Eli Lilly CEO says Medicare coverage of obesity drugs could 'change the game' for upcoming pill launch

Lilly CEO Dave Ricks is confident in the ability of the company's pill to compete and is preparing for a "full launch" in the second quarter.

Eli Lilly CEO David Ricks talks Medicare coverage of obesity pills

Eli Lilly CEO Dave Ricks on Friday said upcoming Medicare coverage of obesity drugs could be a major catalyst for the rollout of the company’s closely watched experimental weight loss pill, orforglipron. In an exclusive interview with CNBC, Ricks said Lilly expects to have Medicare coverage for the treatment “immediately following that launch, and that will change the game a bit too.”  He said that’s because many patients are currently paying in…